Ort der Veranstaltung:
Hörsaalzentrum der TU Dresden
Bergstraße 64, 01069 Dresden

Teilnehmer: 326 aus 29 Ländern


Sponsoren
s. Programm

Referenten/Vorträge
s. Programm
8th Dresden Symposium on Autoantibodies

Dresden, September 12–15, 2007

Final Programme
View to the picturesque Old Town of Dresden, 2007
Dear Colleagues,

On behalf of the organizers, the Medical Faculty of the Technical University Dresden and the „Gesellschaft zur Förderung der Immundiagnostik e.V.“ (Society for the Advancement of Immune Diagnostics), I am honoured and pleased to welcome you to the 8th Dresden Symposium on Autoantibodies.

Disease-associated autoantibodies become more and more important for routine diagnostics as well as basic and applied research. As many of these autoantibodies are detectable long time before clinical manifestations, they may be used to predict the development of the appropriate disease. However their potential role in the very early diagnosis or risk assessment of disease development remains to be further studied. The current Dresden Symposium on Autoantibodies entitled „From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies“ will focus on the current knowledge as well as the perspectives of the prediction of organ specific and systemic autoimmune diseases. For disease prediction and early intervention it is necessary to understand the pathologic processes leading to autoimmune diseases. For instance, components of the innate immune system (e.g. Toll-like receptors) can have a dramatic impact on autoantibody response and disease pathogenesis, either by promoting or by regulating disease. Furthermore, the different effects of autoantibodies in immune homeostasis and autoimmune manifestations will be presented and discussed. Once again, concerning their growing importance, the Dresden meeting will focus on pathologic, diagnostic and prognostic relevance of autoantibodies against citrullinated proteins and peptides. Emerging technologies for the identification of novel autoantibodies as well as for the determination of autoantibodies and autoantibody profiles will be presented and improvement of autoantibody analyses by autoantigen designing and technological innovations will be discussed. Optimized, standardized and cost-effective
multiparametric assays are the prerequisite for the future use of autoantibodies for a more accurate prediction of diseases.

Since the last symposium many exciting changes have happened in Dresden. The reconstruction of the famous “Church of our Lady”, destructed in 1945, is finished. Around the Church you will find a number of new, revived historical buildings reforming the historical New Market silhouette. Next to the Church, the reconstruction of the former Saxonian Royal Residence, also destructed in 1945, is nearly completed. There you can visit the immeasurable, fantastic art treasures and crown jewels of the former Saxonian Kings. We are sure you will enjoy your stay in Dresden.

I am very grateful to all participants for their active contribution. I express my gratitude towards all organisers and sponsors who enabled this symposium. We will do our best to make the 8th Dresden Symposium on Autoantibodies an unforgettable event.

Karsten Conrad
Registration

Welcome and Introductions

INAUGURAL LECTURE
Autoantibodies as predictors of diseases – Past, present, future
N.R. Rose (Baltimore, USA)

COFFEE BREAK

INDUCTION OF AUTOANTIBODIES
Co-Chairs: M. Bachmann (Dresden, Germany)
C.A. Casiano (Loma Linda, USA)

The role of Toll-like receptors in the induction of autoantibodies and the development of autoimmune diseases
M. Ehlers (Berlin, Germany)

Induction of autoimmune responses in animal models of rheumatoid arthritis by inflammatory stimuli
G. Steiner (Vienna, Austria)

Origin of ANCA – New insights
E. Csernok (Bad Bramstedt, Germany)

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

EFFECTS OF AUTOANTIGENS AND AUTOANTIBODIES
Co-Chairs: E. Csernok (Bad Bramstedt, Germany)
F. Blaes (Giessen, Germany)

Protective autoantibodies –
Clinical relevance and therapeutic potential
E. Toubi, Y. Shoenfeld (Haifa, Israel)
Pathophysiology of antiphospholipid antibodies: Interaction with monocytes and activation of procoagulant cytokines and Toll-like receptors

*P. von Landenberg (Mainz, Germany)*

Identification of candidate interacting partners of the stress-response autoantigen DFS70/LEDGF using transcription factor protein arrays

*P. Chatterjee, E.J. Adkins, C.A. Casiano (Loma Linda, USA)*

Characterization of cellular and humoral autoimmune responses to histone H1 and core histones in patients with SLE

*G. Stummvoll, R. Fritsch, B. Meyer, M. Aringer, J. Smolen, G. Steiner (Vienna, Austria)*

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

**EFFECTS OF AUTOANTIBODIES**

Co-Chairs: E. Toubi (Haifa, Israel)

M. Fritzler (Calgary, Canada)

Clinical and pathological significance of autoantibodies against protective molecules

*M. Szyper Kravitz, Y. Shoenfeld (Tel Aviv, Israel)*

Catalytic autoantibodies – Role in immune homeostasis and autoimmune pathogenesis

*S. Suchkov (Moscow, Russia)*

Are autoantibodies secreted by long-lived plasma cells pathogenic?

*F. Hiepe (Berlin, Germany)*

Complex regional pain syndrome and autoantibodies against differentiation-dependent neuronal surface antigens

*F. Blaes, D. Nascimento, K. Schmitz, O. Matz, M. Tschernatsch, M. Kaps (Giessen, Germany)*

Welcome Reception
RECEPTORS, AUTOANTIBODIES, AND DISEASE
Co-Chairs: A. Kromminga (Hamburg, Germany)
K. Conrad (Dresden, Germany)

Anti-receptor autoantibodies in cardiac diseases
M. Fu (Goteborg, Sweden)

Diagnostic and pathogenic relevance of autoantibodies against peptide-hormone receptors
G. Wallukat (Berlin, Germany)

COFFEE BREAK – POSTER AND EXHIBITION VIEWING
Poster viewing
P1 Effects on autoantibodies
P51–P55 Autoantibodies in miscellaneous diseases

AUTOANTIBODIES IN NEUROMUSCULAR AND NEUROLOGICAL DISEASES
Co-Chairs: B. Lang (Oxford, UK)
U. Wurster (Hannover, Germany)

Pathogenic and diagnostic relevance of autoantibodies against ion channels
B. Lang, A. Vincent (Oxford, UK)

Surface-binding autoantibodies and B-cell activating factor (BAFF) in pediatric opsoclonus-myoclonus syndrome
F. Blaes, D. Nascimento, K. Schmitz, O. Matz, M. Tschematsch, M. Kaps (Giessen, Germany)

Anti-neuropil antibody in a patient with limbic encephalitis and breast cancer
THURSDAY
SEPTEMBER 13

12.00–13.30
LUNCH BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing
**P2–P12**  Autoantibodies in neurologic diseases
**P13–P27**  Autoantibodies in gastrointestinal, liver, exocrine and cutaneous diseases

13.30–15.30
AUTOANTIBODIES TO MACROMOLECULAR COMPLEXES
Co-Chairs:  G. Steiner (Vienna, Austria)
            F. Hiepe (Berlin, Germany)

13.30–14.00
Autoantibodies to key components of RNA interference pathway
*E.K.L. Chan (Gainesville, USA)*

14.00–14.30
Autoantibodies to cytoplasmic “somes“: Endosomes, exosomes, aggresomes and the Golgi complex
*M. Fritzler (Calgary, Canada)*

14.30–15.00
Novel aspects of autoantibodies to the human exosome (PM/Scl complex)
*M. Mahler (Neuss, Germany)*

15.00–15.30
The human interferon-inducible protein IFI16 – Autoantigen, autoantibodies and pathophysiological mechanisms
*P.L. Meroni (Milan, Italy)*

15.30–16.20
COFFEE BREAK – POSTER AND EXHIBITION VIEWING

16.20–18.30
METHODICAL ASPECTS AND DIAGNOSTIC STRATEGIES I
Co-Chairs:  N. Bizzaro (Tolmezzo, Italy)
            L.E.C. Andrade (Sao Paulo, Brazil)

16.20–17.00
Strategies and tools to attain early diagnosis and estimate prognosis of autoimmune rheumatic disorders
*A.S. Wiik (Copenhagen, Denmark)*
Elements for the interpretation of a positive autoantibody test in an apparently non-autoimmune individual  
*L. Andrade (São Paulo, Brazil)*

Lessons from autoantibody binding avidity  
*A. Kromminga (Hamburg, German)*

The definition of reference intervals in autoantibody assays using indirect methods based on current data  
*R. Tozzoli (Latisana, Italy)*

Meeting of the German EASI group
PREDICTION AND EARLY DIAGNOSIS OF AUTOIMMUNE DISEASES I
Co-Chairs: M. Ehlers (Berlin, Germany)
          E. Bonifacio (Dresden, Germany)

09.00–09.40  Prediction and prevention of autoimmune diseases – Myth and reality
             Y. Shoenfeld (Tel Aviv, Israel)

09.40–10.10  Autoantibody characteristics and combinations in the prediction of type 1 diabetes
             E. Bonifacio (Dresden, Germany)

10.10–10.25  Differentiation of type 1 diabetes risk by GAD antibody epitope analysis and insulin antibody affinity in antibody positive children from a general population
             M. Schlosser, W. Kerner, P. Achenbach, C.S. Hampe, R. Walther (Greifswald, Germany)

10.25–11.00  COFFEE BREAK – POSTER AND EXHIBITION VIEWING

PREDICTION AND EARLY DIAGNOSIS OF AUTOIMMUNE DISEASES II
Co-Chairs: Y. Shoenfeld (Tel Aviv, Israel)
           P.L. Meroni (Milano, Italy)

11.00–11.40  Autoantibodies, classification criteria and diagnosis of systemic autoimmune diseases
             M. Fritzler (Calgary, Canada)

11.40–12.05  Infections and anti-phospholipid antibodies in prediction of autoimmune disease manifestations
             Y. Sherer (Tel Hashomer, Israel)

12.05–12.30  Diagnostic and predictive value of specific antibodies cross-reacting with a 28-kDa Drosophila antigen
             C. Duftner (Klagenfurt, Austria)

12.30–13.30  LUNCH BREAK – POSTER AND EXHIBITION VIEWING
Poster viewing

**P35–P43**  Autoantibodies in SLE and APS
**P44–P47**  Autoantibodies in systemic sclerosis
**P48–P50**  Autoantibodies in systemic vasculitis

**PREDICTION AND EARLY DIAGNOSIS OF RHEUMATOID ARTHRITIS**

Co-Chairs: M. Aringer (Dresden, Germany)  
P. von Landenberg (Mainz, Germany)

Rheumatoid arthritis – From early diagnosis to early therapy

*J. Rönnelid (Uppsala, Sweden)*

Clinical and pathophysiological relevance of the autoimmune response to citrullinated proteins in rheumatoid arthritis

*G. Serre (Toulouse, France)*

Early diagnosis of rheumatoid arthritis by autoantibodies against citrullinated protein/peptide

*W.J. van Venrooij (Nijmegen, The Netherlands)*

Diagnostic and prognostic value of autoantibodies against Sa/cit-vimentin

*H.A. Menard (Montreal, Canada)*

**COFFEE BREAK - POSTER AND EXHIBITION VIEWING**

Poster viewing

**P28–P34**  Autoantibodies in rheumatoid arthritis

**Departure to Meissen Castle**

Guided walking tour

Social Dinner
SATURDAY
SEPTEMBER 15

09.00–10.00
NOVEL AUTOANTIBODIES
Co-Chairs: E.K.L. Chan (Gainesville, USA)
M. Mahler (Neuss, Germany)

Discovery and validation of novel disease-associated autoantibodies using protein array technologies
J. Beator (Dortmund, Germany)

Identification of two new autoantigens in patients with high titres of antinuclear antibodies using protein macroarray technology
C. Hempp, F. Haag, F. Koch-Nolte, T. Krieger (Hamburg, Germany)

Sera of glaucoma patients show complex autoantibody profiles against human retina and optic nerve antigens
S.C. Joachim, J. Reichelt, S. Berneiser, N. Pfeiffer, F.H. Grus (Mainz, Germany)

10.00–11.00
COFFEE BREAK – POSTER AND EXHIBITION VIEWING

Poster viewing
P56–P57 Identification of novel autoantibodies
P58–P66 Multiparametric autoantibody determination

11.00–12.15
METHODICAL ASPECTS AND DIAGNOSTIC STRATEGIES II
Co-Chairs: U. Sack (Leipzig, Germany)
L. Cebecauer (Piestany, Slovak Republic)

Proteomics on a chip for monitoring autoimmune diseases

Sensitive and specific detection of pemphigoid autoantibodies by an Enzyme-linked immunosorbent assay using multimers of the NC16A domain of BP180 as antigen
Deamidated gliadin peptides are superior to native gliadin in ELISA for diagnosis of childhood coeliac disease

Antibodies against nucleosomes and DNA: Clinical and pathogenic significance
L. Cebecauer, I. Lochmann, V. Kral, R.W. Burlingame, W. Schlumberger (Piestany, Slovak Republic)

Can anti-chromatin antibody ELISA replace FARR in a routine diagnostic laboratory?
M. Spellerberg, M. Hayman, P. Chapman, L. Stamp, J. O’Donnell (Christchurch, New Zealand)
POSTER EXHIBITION

Effects of autoantibodies

**P1**  Catalytic autoantibodies in organ-specific autoimmunity: an update  
*E. Tretyak, S. Suchkov (Moscow, Russia)*

Neuromuscular and neurologic diseases

**P2**  Paraneoplastic limbic encephalitis with anti-MA2 and CV2 antibodies  
*B. Giometto, M. Zoccarato, L. Zuliani, R. Vitaliani (Padova, Italy)*

**P3**  Long term survival of two patients with small cell lung carcinoma and anti-Hu antibodies. Relation to therapy and serial antibody determination  
*U. Wurster, J. Tümmler, E. Sindern, A. Borchert, M. Schilling (Hannover, Germany)*

**P4**  Possible implementation of diagnostic tools in paraneoplastic neurological disorders  
*D. Saccomanno, G.P. Comi, N. Bresolin, M. Carpo (Milan, Italy)*

**P5**  EUROLINE Neuronal Antigens: A newly developed line immunoassay for the detection of antibodies against neuronal antigens in paraneoplastic syndromes  
*T. Scheper, W. Meyer, P. Klatt, L. Komorowski, C. Probst, W. Schlumberger, W. Stöcker (Lübeck, Germany)*

**P6**  Antineurofilament antibodies in cerebrospinal fluid and serum in patients with amyotrophic lateral sclerosis  
*I. Malbohan, L. Fialová, J. Varcová, A. Barto, P. Ridzo, R. Rusina (Prague, Czech Republic)*

**P7**  Avidity of antineurofilament antibodies determined by ELISA method  
*I. Malbohan, J. Varcová, L. Fialová, A. Barto (Prague, Czech Republic)*
P8 Anti-ganglioside autoantibodies profiling in patients with autoimmune peripheral neuropathies by a new line immunoassay
H. Schneider, K. Conrad, T. Ziemssen, T. Talaska, D. Reinhold, R.-L. Humbel, D. Roggenbuck (Dresden, Germany)

P9 Detection of anti-MOG autoantibodies in acute disseminated encephalomyelitis (ADEM) by FACS analysis using MOG-transfected LN18 cells
P. W. Modderman, L.A. Aarden, R.Q. Hintzen, D. Hamann (Amsterdam, The Netherlands)

P10 Discovery and validation of novel Multiple Sclerosis associated biomarkers using protein biochips
A. Lüking, C. Gutjahr, K. Schulte, V. Gruß, H.E. Meyer, C. Huels, S. Müllner, J. Beator (Dortmund, Germany)

P11 Neurological complications in celiac disease: could have an autoimmune origin?
M. Carpo, D. Saccomanno, M.T. Bardella, S. Allaria, N. Bresolin, G.P. Comi (Milan, Italy)

P12 Spectrum of autoantibodies in patients with psychiatric manifestations
L. Laadhar, O. Sidhorn, S. Masmoudi, M. Zitouni, M. Kallel Sellami, H. Zoubei, S. Makni (Tunis, Tunisia)

Gastrointestinal and liver diseases

P13 Anti-carbohydrate antibodies as a new marker for inflammatory bowel disease
K. Malickova, P.L. Lakatos, R. Donoval, P. Sandova, I. Janatková, M. Lukas, (Prague, Czech Republic)

P14 Differential diagnosis between Crohn’s Disease vs non Crohn’s Disease patients using a combination of Antiglycan Antibodies (gASCA, ALCA, ACCA and AMCA)
M. Franco, M. Ramalho, S.F. Alberto, L. Novais, G. de Sousa, J.R. de Deus (Amadora, Portugal)
P15 Aberrant expression of B cell-activating factor of the TNF family (BAFF) and its receptor in duodenal biopsies of patients with celiac disease

P16 Overexpression of B cell-activating factor of the TNF family (BAFF) in serum and duodenal biopsy in celiac disease patients

P17 Antibodies against deamidated gliadin peptides as novel biomarkers of childhood coeliac disease

P18 Deamidated gliadin peptides are superior to native gliadin in ELISA for diagnosis of childhood coeliac disease

P19 Screening for celiac disease in patients with Hashimoto thyroiditis
L. Laadhar, F. Harzallah, A. Hassin, M. Zitouni, M. Kallel-Sellami, S. Masmoudi, H. Slimane, S. Makni (Tunis, Tunisia)

P20 Production of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits
S. Stenman, K. Lindfors, I.R. Korponay-Szabo, O. Lohi, H. Wieser, M. Mäki, K. Kaukinen (Tampere, Finland)

P21 Coeliac disease-specific IgA class autoantibodies disturb angiogenesis
E. Myrsky, K. Kaukinen, M. Syrjänen, I.R. Korponay-Szabo, M. Mäki, K. Lindfors (Tampere, Finland)
P22  Detection of primary biliary cirrhosis-associated antimitochondrial antibodies using an improved test system: anti-M2/BPO ELISA
L. Komorowski, D. P. Bogdanoz, C. Probst, C. Dähnrich, A. Rosemann, W. Schlumberger, W. Stöcker (Lübeck, Germany)

P23  A help on primary biliary cirrhosis diagnosis? Comparison between a newly developed ELISA (PBC screen) to the sp100, gp210 ELISAs

P24  A comprehensive line immunoassay for the detection of autoantibodies in primary biliary liver cirrhosis (PBC)

Endocrine diseases

P25  Examination of the diabetes-associated autoantigen GAD65 in serum as a possible early diagnostic marker of beta cell loss
U. Walschus, I. Klöting, R. Walther, M. Schlosser (Greifswald, Germany)

Cutaneous autoimmune diseases

P26  Prevalence of autoantibodies in patients with pemphigus
K. Mejri, M. Kallel Sellami, L. Laadhár, H. Lahmer, M. Zitouni, S. Makni (Tunis, Tunisia)

P27  Successfull anti-CD20 therapy in paraneoplastic pemphigus associated with a follicular dendritic cell sarcoma
R. Bailloud, J. Serratrice, S. Desplat-Jégo, P. Thomas, P.-J. Weiller (Marseille, France)
**Rheumatoid arthritis and other arthropathies**

**P28** The synovial citrullinome of rheumatoid arthritis patients  

**P29** Comparison of anti-mutated citrullinated vimentin antibodies with anti-CCP antibodies: interest in RA diagnosis and during infliximab therapy  
*P. Nicaise-Roland, S. Grootenboer-Mignot, A. Bruns, M. Hurtado, E. Palazzo, G. Hayem, O. Meyer, S. Chollet-Martin (Paris, France)*

**P30** Improvement of serological RA diagnostics by autoantibody profiling  
*K. Conrad, R. Christoph, B. Roch, K. Lüthke, B. Heschel, S. Bornstein, H.E. Schröder (Dresden, Germany)*

**P31** Cost effectiveness of autoantibodies against cyclic citrullinated peptide in the very early diagnosis of rheumatoid arthritis  
*A. Konnopka, K. Conrad, C. Baerwald, G. Kobelt, H.-H. König (Leipzig, Germany)*

**P32** Characterization of cells expressing citrullinated proteins in synovial tissue of patients with rheumatoid arthritis, reactive arthritis, psoriatic arthritis and osteoarthritis  
*C. Zimmermann, M. Tohidast-Akrad, P. Zenz, J. Smolen, G. Steiner (Vienna, Austria)*

**P33** Hypothesis-testing for etiopathogenesis, therapy and prevention of ankylosing spondylitis, Klebsiella-reactive uveitis and rheumatoid arthritis  
*F. Hartig, R. Pechlaner (Innsbruck, Austria)*

**P34** Autoantibody profile in slovak patients with juvenile idiopathic arthritis  
*D. Kozáková, V. Bosák, E. Kosková, F. Mateicka (Piestany, Slovak Republic)*
SLE and antiphospholipid syndrome

P35 Evaluation of novel assay systems for the determination of autoantibodies to double-stranded DNA in patients with SLE
C. Zimmermann, E. Hoefler, J. Smolen, G. Steiner (Vienna, Austria)

P36 A novel dot assay for the detection of anti-dsDNA antibodies in SLE sera
T. Lüttich, P. Eissfeller, C. Jauris, A. Kromminga (Neuried, Germany)

P37 Characterization of cellular and humoral autoimmune responses to histone H1 and core histones in patients with SLE
G. Stummvoll, R. Fritsch, B. Meyer, M. Aringer, J. Smolen, G. Steiner (Vienna, Austria)

P38 Cryopreservation of crithidia luciliae
S. Carujo, A. Belén Polonio, P. Munujos (Barcelona, Spain)

P39 High sensitive detection of dsDNA antibodies by a modified CLIFT
W. Schößler, T. Büttner, D. Roggenbuck, K. Conrad (Berlin, Germany)

P40 Anti-C1q antibodies: prevalence and follow up of antibody levels in patients with biopsy-proven lupus nephritis.
M. Sanmarco, N. Bardin, P. Giaime, P. Brunet, L. Daniel, Y. Berland (Marseille, France)

P41 The association of anti-SS-A/Ro52 and anti-SS-A/Ro60 antibodies in different connective tissue diseases
P. Eissfeller, J. Bartel, T. Lüttich, C. Jauris, M.J. Fritzler (Neuried, Germany)

P42 Evaluation of novel chemiluminescence-based methods for the detection of anti-cardiolipin antibodies in APS and SLE patients
A.W. Götz, F. Capuano, L. Pallavicini, K. Conrad, K. Tausche, H.E. Schröder (Dietzenbach, Germany)
P43  Value of serum levels of autoantibodies for monitoring therapy with aphaeresis in antiphospholipid syndrome (APS)
M. Tampoia, A. Ramunni, A. Zucano, P. Lisi, G. Pannarale, A. Fontana (Bari, Italy)

Systemic sclerosis

P44  Evaluation of an enzyme immunoassay for the detection of scleroderma-related autoantibodies
R. Tozzoli, G. Kodermaz, N. Bizzaro, E. Tonutti, M. Tampoia, S. Platzgummer, A. Antico (Latisana, Italy)

P45  RNA polymerase III antibodies in patients with systemic sclerosis: validation of a new ELISA method

P46  Anti-Scl70 antibody levels correlate with skin and organ fibrosis in patients with systemic sclerosis – analysis from the Charité SSc cohort
S. Uibel, K. Hanke, C. Dähnrich, C. Brückner, K. Egerer, F. Hiepe, W. Schlumberger, G. Riemekasten (Berlin, Germany)

P47  Antibodies against CENP-B antigen identify a subset of systemic sclerosis patients with sicca syndrome and missing lung fibrosis – analysis of the Charité SSc cohort
K. Hanke, S. Uibel, C. Brückner, C. Dähnrich, K. Egerer, F. Hiepe, W. Schlumberger, G. Riemekasten (Berlin, Germany)

ANCA-associated vasculitis

P48  MPO and PR3 autoantibodies: evaluation of a new indirect immunofluorescence method
F. Gioia, D. De Francesco (Busto Arsizio, Italy)
P49 EUROPLUS™ ANCA BIOCHIP Mosaic: MPO and PR3 antigen dots improve the detection of ANCA by indirect immunofluorescence

P50 A newly developed ELISA using a mixture of native PR3 and recombinant PR3 expressed in human cells improves the serological investigation of ANCA-associated vasculitis

Miscellaneous diseases

P51 Anti-GSTT1 antibody mediated chronic renal allograft rejection
I. Wichmann, I. Aguilera, A.J. Alvarez-Marquez, M.A. Gentil, A. Nuñez-Roldan (Sevilla, Spain)

P52 The antinuclear autoantibodies in patients with chronic heart failure
N. Virstyuk, E. Cherkachuna (Ivano-Frankivsk, Ukraine)

P53 Determination of serum anti-S100 autoantibodies in patients with acute ischemic stroke
M. Cojocaru, I.M. Cojocaru, C. Burcin, A. Atanasiu (Bucharest, Romania)

P54 Prevalence and clinical significance of autoantibodies in 147 adult patients with cystic fibrosis
K. Nkana, F. Lachenal, J.R. Nove, I. Durieu, N. Fabien (Pierre Benite, France)

P55 High prevalence of autoantibodies in patients with sickle cell disease
Identification of novel autoantibodies

P56  Identification of novel autoantibodies
Protein arrays as versatile tool for the characterization of antibodies
A. Kowald (Bochum)

P57  Anti-prostasome autoantibodies in serum from prostate cancer patients
K.G. Ronquist, L. Carlsson, G. Ronquist, A. Larsson (Uppsala, Sweden)

Multiplex assays for autoantibody analyses

P58  Multiplex assays for autoantibody analyses
Development of a novel multi-parameter platform for use in autoimmune diseases – technical aspects and first results on ANA testing
U. Klause, M. Rothfuss, H. Eberl, M. Wanger, A. Nichtl, H.-J. Müller, B. Risse (Penzberg, Germany)

P59  Multiplex assays for autoantibody analyses
Evaluation of ANA - ENA antibodies in sera of patients with Sjögren’s syndrome using two multiplexed immunoassays (athena multi-lyte ANA system and the FIDISTM connective) and two conventional methods (ouchterlony double immunodiffusion, immunoblotting)
I. Abreu, H. Guimarães, A. Bastos, V. Pato, F. Barcelos, G. Sousa, H. Trindade (Lisbon, Portugal)

P60  Multiplex assays for autoantibody analyses
BioPlex™2200 system: simultaneous detection of anti-dsDNA and anti-nucleosome antibodies in patients with systemic lupus erythematosus
N. Bardin, S. Desplat-Jego, B. Larida, M. Sanmarco (Marseille, France)

P61  Multiplex assays for autoantibody analyses
Comparison between UltraPlex™ barcoded micro-particle technology and enzyme-linked immunosorbent assay for the determination of antibodies to dsDNA and extractable nuclear antigens
T. Witte, J. Smith, D. Mosedale, R.E. Schmidt (Hannover, Germany)
**P62** Evaluation of multiplexed fluorescence microsphere immunoassay for detection of autoantibodies to nuclear antigens
*A. Kozmar, M. Rudolf, I. Radic, B. Malenica* (Zagreb, Croatia)

**P63** EUROLEINE Myositis Profile: A newly developed line immunoassay for the detection of myositis specific autoantibodies

**P64** Microblots for autoantibody differentiation

**P65** HEp-2 cell preparation for automated analysis of autoantibodies

**P66** Autoantibody screening by indirect immunofluorescence on Hep-2 cells: Comparison of a novel automated image processing with visual examination
<table>
<thead>
<tr>
<th>Informations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Venue</strong></td>
<td>The modern Lecture Hall Centre of the Technical University of</td>
</tr>
<tr>
<td></td>
<td>Dresden is located on the University Campus in the South of the</td>
</tr>
<tr>
<td></td>
<td>city, about 15 minutes walk away from the Central Railway Station.</td>
</tr>
<tr>
<td><strong>Address of the congress venue:</strong></td>
<td>Hörsaalzentrum der Technischen Universität Dresden</td>
</tr>
<tr>
<td></td>
<td>Bergstrasse 64, D-01069 Dresden</td>
</tr>
<tr>
<td><strong>Registration office</strong></td>
<td>September 12: 08.00–21.30</td>
</tr>
<tr>
<td></td>
<td>September 13: 08.00–19.00</td>
</tr>
<tr>
<td></td>
<td>September 14: 08.00–16.30</td>
</tr>
<tr>
<td></td>
<td>September 15: 08.00–13.00</td>
</tr>
<tr>
<td><strong>Phone/Fax on site</strong></td>
<td>Phone +49 351 463 48812</td>
</tr>
<tr>
<td></td>
<td>Fax +49 351 463 48814</td>
</tr>
<tr>
<td><strong>Chairman</strong></td>
<td>Karsten Conrad, Germany</td>
</tr>
<tr>
<td><strong>Co-Chairmen</strong></td>
<td>Edward K. L. Chan, USA</td>
</tr>
<tr>
<td></td>
<td>Marvin Fritzler, Canada</td>
</tr>
<tr>
<td></td>
<td>Yehuda Shoenfeld, Israel</td>
</tr>
<tr>
<td></td>
<td>Allan S. Wiik, Denmark</td>
</tr>
<tr>
<td><strong>International Advisory Board</strong></td>
<td>Luis E. C. Andrade, Brazil</td>
</tr>
<tr>
<td></td>
<td>Michael Bachmann, Germany</td>
</tr>
<tr>
<td></td>
<td>Nicola Bizzaro, Italy</td>
</tr>
<tr>
<td></td>
<td>Elena Csernok, Germany</td>
</tr>
<tr>
<td></td>
<td>Falk Hiepe, Germany</td>
</tr>
<tr>
<td></td>
<td>Arno Kromminga, Germany</td>
</tr>
<tr>
<td></td>
<td>Pier Luigi Meroni, Italy</td>
</tr>
<tr>
<td></td>
<td>Günter Steiner, Austria</td>
</tr>
<tr>
<td></td>
<td>Walter J. van Venrooij, The Netherlands</td>
</tr>
<tr>
<td><strong>Language</strong></td>
<td>English, no simultaneous translation</td>
</tr>
<tr>
<td><strong>City map</strong></td>
<td>see: <a href="http://www.gfid-ev.de">www.gfid-ev.de</a></td>
</tr>
</tbody>
</table>
Informations

Organization
(Registration, Reservation, Exhibition)

Registration fee

Participants EUR 400
GFID members EUR 330
Students/Residents EUR 210
One day tickets EUR 140

(includes unlimited access to all scientific sessions, welcome reception, industrial exhibition, 5th volume of the book series "Autoantigens, Autoantibodies, Autoimmunity", coffee and lunch breaks)

Members of the Dresden University are free of charge.

Social programme

Welcome reception in the Lecture Hall Center of the Technical University of Dresden

Guided tour and Social Dinner in the Meissen Castle (30 €)
The establishment of the Meissen Castle goes back to the year 929. In 1470, the brilliant master-builder Arnold von Westfalen created a late gothic castle complex, the first palatial castle of its kind in German building history. Between 1710 and 1863, the castle was the first domicile of the famous Meissen porcelain factory. Before the Social Dinner in the prestigious Central Hall of the Meissen Castle we offer a guided walking tour visiting the Castle museum.

16.30 h: Departure by bus starting from the congress venue. Please note that because of the geographical conditions in Meissen we have to walk approximately 10–15 min from the bus stop to the castle. Please use appropriate footwear.

Wednesday, September 12, 2007
19.00

Friday, September 14, 2007
17.30
The following companies participate in the industrial exhibition and/or have made a generous sponsoring (in alphabetical order):

**A. MENARINI DIAGNOSTICS DEUTSCHLAND.**
Division der BERLIN-CHEMIE AG (Berlin, Germany)
www.menarini.com

**AID Autoimmun Diagnostika GmbH**
(Strassberg, Germany)
www.aid-diagnostika.com

**Attomol GmbH**
(Lipten, Germany)
www.attomol.de

**BIO-RAD Laboratories, Inc.**
(Hercules, USA)
www.bio-rad.com

**BioSystems S.A.**
(Barcelona, Spain)
www.biosystems.com

**Bühlmann Laboratorien AG**
(Schönenbuch, Switzerland)
www.buhlmannlabs.ch

**DIAMED DIAGNOSTIKA Med. Produkte GmbH**
(Bensheim, Germany)
www.diamed.de

**DiaSorin Deutschland GmbH**
(Dietzenbach, Germany)
www.diasorin.com

**EUROIMMUN Medizinische Labordiagnostika AG**
(Lübeck, Germany)
www.euroimmun.de

**GA Generic Assays GmbH**
(Dahlewitz, Germany)
www.genericassays.com
HUMAN GmbH
(Wiesbaden, Germany)
www.human.de

Immundiagnostik AG
(Bensheim, Germany)
www.immundiagnostik.com

INOVA Diagnostics, Inc.
(San Diego, USA)
www.inovadx.com

in.vent DIAGNOSTICA GmbH
(Hennigsdorf, Germany)
www.inventdiagnostica.de

ORGENTEC Diagnostika GmbH
(Mainz, Germany)
www.orgentec.com

Phadia GmbH
(Freiburg, Germany)
www.phadia.com

Pronostics Ltd.
(Cambridge, UK)
www.pro-nostics.com

The Binding Site GmbH
(Schwertingen, Germany)
www.bindingsite.com

Viramed Biotech AG
(Planegg, Germany)
www.viramed.de

We thank these companies for helping to make this symposium successful.